Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation
Publication date
2020-08
Authors
Sallevelt, Bastiaan T G
Teunis, Teun
Agterof, Mariette J
van den Broek, Marcel P H
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
WHAT IS KNOWN AND OBJECTIVE: Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate. CASE SUMMARY: We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation. WHAT IS NEW AND CONCLUSION: We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.
Keywords
antibody-drug conjugate, chemotherapy, epidermal necrosis, extravasation, oncology, trastuzumab-emtansine, Case Reports
Citation
Sallevelt, B T G M, Teunis, T, Agterof, M J & van den Broek, M P H 2020, 'Extravasation of an antibody-drug conjugate : A case report of epidermal necrosis after trastuzumab-emtansine extravasation', Journal of Clinical Pharmacy and Therapeutics, vol. 45, no. 4, pp. 832-835. https://doi.org/10.1111/jcpt.13148